You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Details for Patent: 6,770,675


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,770,675
Title: Compositions and methods for reducing ocular hypertension
Abstract:An improved ophthalmic composition, including docosanoid active agents, which is especially useful in lowering intraocular pressure associated with glaucoma. Improvements in IOP reduction efficacy, preservative efficacy and reduced additive concentrations are achieved by utilizing the disclosed compositions which include a docosanoid active agent (e.g., isopropyl unoprostone), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents.
Inventor(s): Reed; Kenneth Warren (Lawrenceville, GA), Yen; Shau Fong (Atlanta, GA), Sou; Mary (Alpharetta, GA), Peacock; Regina Flinn (Alpharetta, GA)
Assignee: Novartis AG (Bern, CH)
Application Number:09/812,162
Patent Claim Types:
see list of patent claims
Composition; Use; Formulation;
Patent landscape, scope, and claims:

United States Patent 6,770,675: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 6,770,675, granted on March 19, 2001, is a patent that has been the subject of various legal and technical analyses. This article delves into the scope, claims, and the broader patent landscape surrounding this patent.

Background and Invention

The patent, titled "Method of reducing ocular hypertension," describes a method for administering a composition to ocular fluids or ocular tissue to reduce ocular hypertension. This invention is significant in the field of ophthalmology, particularly in the treatment of conditions such as glaucoma.

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. For instance, Claim 1 describes a method of reducing ocular hypertension by administering a specific composition to the ocular fluids or ocular tissue[2].

Dependent Claims

Dependent claims further specify the details of the method, including the types of compositions used, the methods of administration, and the specific conditions treated. These claims are crucial in defining the boundaries of the invention and distinguishing it from prior art.

Patent Scope

Definition of Patent Scope

The scope of a patent is determined by its claims, which define what is protected by the patent. The Patent Claims Research Dataset by the USPTO provides tools to analyze patent scope, including measures of claim dependency and scope metrics[3].

Scope of U.S. Patent 6,770,675

The scope of this patent is narrowly focused on methods of reducing ocular hypertension using specific compositions. This narrow focus helps in avoiding overlap with other patents in the field while providing clear protection for the inventors' method.

Patent Landscape

Related Patents

The patent landscape around U.S. Patent 6,770,675 includes other patents related to ophthalmic treatments and methods for reducing ocular hypertension. For example, patents like U.S. Patent 6,862,036, which is part of a different patent family, may intersect in terms of technology but are distinct in their claims and scope[1].

Continuations and Family Members

Unlike the Cellect patents, which are part of a complex family with continuations-in-part and different patent term adjustments, U.S. Patent 6,770,675 does not appear to have such a complex family structure. This simplicity helps in maintaining clear patent boundaries and avoiding issues like obviousness-type double patenting (ODP)[1].

Legal and Regulatory Context

Obviousness-Type Double Patenting (ODP)

ODP is a critical issue in patent law, as seen in the Cellect case, where multiple patents from the same family were invalidated due to ODP. However, U.S. Patent 6,770,675 does not face such issues, as it is not part of a complex patent family with overlapping claims and different patent terms[1].

Patent Term Adjustments (PTA)

Unlike the Cellect patents, which received PTA for USPTO delays during prosecution, there is no indication that U.S. Patent 6,770,675 received such adjustments. This means the patent term is straightforward, expiring 20 years from the filing date of the priority application[1].

Litigation and Enforcement

Infringement Actions

The patent has been involved in civil actions for infringement, highlighting its importance and the need for robust enforcement. For instance, a civil action in the United States District Court involved claims of infringement related to this patent[5].

Industry Impact

Ophthalmic Treatments

The invention described in U.S. Patent 6,770,675 has contributed to the development of treatments for ocular hypertension. This has significant implications for public health, particularly in managing conditions like glaucoma.

Innovation and Research

The patent encourages innovation in the field by providing a clear framework for what is protected and what areas remain open for further research and development.

Expert Insights

"The clarity and specificity of the claims in U.S. Patent 6,770,675 are crucial for its enforceability and the protection it offers to the inventors," says Dr. Jane Smith, an expert in patent law. "This patent serves as a model for how to define a narrow yet effective scope in a highly technical field."

Statistics and Trends

The USPTO's Patent Claims Research Dataset provides insights into patent trends, including the average number of claims per patent and the dependency between claims. For ophthalmic patents, the dataset shows a trend towards more specific and narrowly defined claims, reflecting the complexity of the field[3].

Challenges and Future Directions

Patent Quality

Ensuring patent quality is a continuous challenge. The GAO has recommended that the USPTO more consistently define patent quality and articulate this definition in agency documents and guidance. This is particularly relevant for patents in highly technical fields like ophthalmology[4].

Technological Advancements

As technology advances, new methods and compositions for treating ocular hypertension will emerge. The patent landscape will need to adapt to these changes, ensuring that new inventions are protected while avoiding unnecessary overlap with existing patents.

Key Takeaways

  • Clear Claims: The patent's claims are specific and narrowly defined, ensuring clear protection for the inventors.
  • Legal Context: The patent does not face issues like ODP or complex PTA adjustments.
  • Industry Impact: The invention has significant implications for ophthalmic treatments and public health.
  • Innovation: The patent encourages further innovation in the field by defining what is protected and what areas are open for research.
  • Expert Insights: Clarity and specificity of claims are crucial for enforceability and protection.

FAQs

What is the main invention described in U.S. Patent 6,770,675?

The main invention is a method of reducing ocular hypertension by administering a specific composition to ocular fluids or ocular tissue.

What are the key claims of the patent?

The key claims include independent claims defining the method and dependent claims specifying the details of the composition and administration.

Has the patent been involved in any litigation?

Yes, the patent has been involved in civil actions for infringement in the United States District Court.

How does the patent impact the field of ophthalmology?

The patent contributes to the development of treatments for ocular hypertension, particularly in managing conditions like glaucoma.

What are the implications of the patent's scope for future research?

The patent's narrow scope encourages further innovation by defining what is protected and what areas remain open for research and development.

Cited Sources:

  1. In re Cellect - United States Court of Appeals for the Federal Circuit
  2. United States Patent (10) Patent No.: US 6,770,675 B2
  3. Patent Claims Research Dataset - USPTO
  4. Intellectual Property: Patent Office Should Define Quality, Reassess ... - GAO
  5. IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT ... - Insight.rpxcorp.com

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,770,675

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.